Bundled payments for chronic diseases increased health care expenditure in the Netherlands, especially for multimorbid patients

•The Netherlands introduced bundled payments for chronic diseases in 2010.•These were expected to improve integration of care and reduce healthcare expenditure.•Their long-term effects were unknown.•The bundled payments led to an increase in total healthcare expenditure.•This increase was higher in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Health policy (Amsterdam) 2021-06, Vol.125 (6), p.751-759
Hauptverfasser: Karimi, Milad, Tsiachristas, Apostolos, Looman, Willemijn, Stokes, Jonathan, Galen, Mirte van, Rutten-van Mölken, Maureen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•The Netherlands introduced bundled payments for chronic diseases in 2010.•These were expected to improve integration of care and reduce healthcare expenditure.•Their long-term effects were unknown.•The bundled payments led to an increase in total healthcare expenditure.•This increase was higher in patients with multimorbidity. Bundled payments aim to stimulate the integration of healthcare services and ultimately reduce healthcare expenditure growth through improved quality of care. The Netherlands introduced bundled payments for chronic diseases in 2010 by reimbursing providers annually for a bundle of primary care services related to COPD, Diabetes, or Vascular Risk Management. We aimed to assess the long-term effects of these bundled payments on healthcare expenditure. We used health insurance claims data from 2008 to 2015 to compare the healthcare expenditure between everyone who was included in bundled payments and a control group. We performed a difference-in-difference analysis in combination with propensity score matching and found that bundled payments consistently increased health care expenditure over seven years. The average half-year increase was €233 (95%CI: 204-262) for DM2, €609 (95%CI: 533-686) for COPD, and €231 (95%CI: 208-254) for VRM, representing 13%, 52%, and 20% of 2008 half-year cost. The increase was higher for those with multimorbidity compared to those without multimorbidity. This suggests that the expectations of the bundled payments are yet to be fulfilled.
ISSN:0168-8510
1872-6054
DOI:10.1016/j.healthpol.2021.04.004